Tag: BioCryst Pharmaceuticals Inc.

  • Early Morning Vibes: Don’t Miss These 3 Value Stocks

    Early Morning Vibes: Don’t Miss These 3 Value Stocks

    Previous Day Trading

    On December 3, the US stock exchanges closed without significant changes. The S&P 500 index dropped 0.06% to 3667 points. Dow Jones added 0.29%, NASDAQ rose 0.23%. There were no new traffic drivers, and macro statistics were mixed. The utilities sector became an outsider, shedding 1.1%. This is the only sector in the S&P 500 to show negative dynamics in the last month due to capital flows from defensive to cyclical sectors.

    Companies News

    • The quarterly results of the cloud cybersecurity companies Zscaler (ZS: + 26.5%) and CrowdStrike (CRWD: + 13.6%) significantly exceeded expectations, as did their forecasts for the next quarter. The demand for cybersecurity is increasing.
    • Boeing (BA: + 6%) awarded its first 737 MAX contract since restrictions were imposed 20 months ago for low-cost airline Ryanair.
    • Data collection and management software developer Splunk (SPLK: -23.3%) released a weak quarterly report, citing a pandemic among negative factors.

    Today, world stock exchanges are showing mostly positive dynamics. The prospect of new fiscal stimulus remains a supportive factor, especially for cyclical sectors. Donald Trump’s rhetoric suggests that he will support any agreement between Democrats and Republicans. Mitch McConnell expressed hope yesterday after meeting with Republican senators that a compromise on a new fiscal stimulus package would be reached.

    Meanwhile, the epidemiological situation in the United States continues to deteriorate. Yesterday, 210 thousand infected with COVID-19 were recorded across the country, and this is a new record. The increase in the number of deaths in patients with coronavirus is also causing pessimism. The Governor of California has warned that new state quarantine measures may be introduced over the next few days. In addition, market participants are concerned that pharmaceutical giant Pfizer may not be able to cope with the production of the vaccine in the planned volume. Thus, the situation on the stock market is controversial. To determine the short-term direction of movement, today’s statistics on the labor market, which investors are looking forward to, can help. If the data reflects the weak impact of the COVID-19 factor, it will increase the risk appetite in the stock market.

    Japan’s Nikkei dropped 0.22%, China’s CSI300 rose 0.18%, and Hong Kong’s Hang Seng climbed 0.40%. European indices are growing. EuroStoxx 50 adds 0.3%.

    The 10-year Treasury rate is reduced to 0.92%. Brent oil futures rise to $ 49.7. Gold rises in price to $ 1840.

    Economic UPDATE

    The US labor market report for November is due today. 469 thousand new jobs are expected to appear against 638 thousand in October, which will mean a slowdown in hiring rates to the lowest since May under the influence of a new wave of the epidemic. The unemployment rate, according to the consensus, will decline from 6.9% to 6.8%.

    Top Movers

    Cinedigm (CIDM) share price is up 60.71% in Friday’s premarket session after reporting that the Company’s eight additional linear streaming channels are now available on Rad’s fast-growing global streaming platform.

    In today’s premarket, BioCryst Pharmaceuticals, Inc. (BCRX) reported 24.83% gain following announcement of FDA approval of ORLADEYO (berotralstat), first oral, once-daily therapy to prevent attacks in Hereditary Angioedema patients.

    NIO Inc. (NIO) share price increased 0.31% in premarket today. An electric vehicles maker recently reported that it delivered 5,291 vehicles in November 2020, a new monthly record representing a solid 109.3% year-over-year growth.

    Analysts Upgrades and Downgrades

    Raymond James turned bullish on Weyerhaeuser Company (WY), upgrading the stock to “Outperform”.

    Sage Therapeutics Inc. (SAGE) has won the favor of Mizuho’s equity research team. The firm upgraded the shares from Neutral to Buy and moved their price target to $81.0, suggesting 16.63% additional upside for the stock.

    Waddell & Reed Financial Inc. (WDR) received an upgrade from analysts at Morgan Stanley. They changed their rating on WDR to Equal-Weight from Underweight in a recently issued research note.

    Earlier Friday Chardan Capital reduced its rating on Mesoblast Limited (MESO) stock to Sell from Neutral and assigned the price target to $7.5. With shares trading at around $15.74, the Wall Street firm thinks Mesoblast Limited’s stock could decline more than 59.19%.

    Latest Insider Activity

    Micron Technology Inc. (MU) EVP, Technology & Products Deboer Scott J announced the sale of shares taking place on Dec 03 at $70.72 for some 10,000 shares. The total came to more than $0.71 million.

    The Walt Disney Company (DIS) EVP, Control, Fin Plan & Tax WOODFORD BRENT sold on Dec 02 a total 34,620 shares at $153.85 on average. The insider’s sale generated proceeds of almost $0.77 million.

    Isoray Inc. (ISR) CEO Woods Lori A declared the purchase of shares taking place on Nov 30 at $0.38 for some 68,000 shares. The transaction amount was around $25534.0.

    CNX Resources Corporation (CNX) EVP & Chief Financial Officer Rush Donald W. bought on Dec 03 a total 263,608 shares at $8.99 on average. The purchase cost the insider an estimated $49,452.

    Earnings To Watch Today

    Top US earnings releases scheduled for today include HD Supply Holdings Inc. (NASDAQ:HDS). It will announce its Oct 2020 financial results. The company is expected to report earnings of $0.47 per share from revenues of $833.56M in the three-month period.

    Analysts expect Big Lots Inc. (NYSE:BIG) to report a net income (adjusted) of $0.66 per share, when the bank releases its quarterly results shortly. Revenue for the fiscal quarter ended Oct 2020 is predicted to come in at $1.35B.

    Huazhu Group Limited (HTHT), due to announce earnings before the market closes today, is expected to report earnings of $0.15 per share from revenues of $470.05M recently concluded three-month period.

  • 18 Biotech Stocks That Are Great Options To Invest In

    18 Biotech Stocks That Are Great Options To Invest In

    The biotech industry is considered to be an attractive industry for the investor. This industry is continuously adopting new technological advancements. As time passes by every aspect of daily existence experience changes because of new technological breakthroughs and advancement in knowledge. Technology plays an important role in changing the lifestyle of humans. This technology also plays a very important role in the biotech industry.

    This technology has historically grown quickly. The biotech industry is striving to develop a treatment for complex diseases. It is anticipated that in 2021, one of the continuing trends in biotech is the continued improvement and development of drug research. The new technology help researchers to improve and assess diagnosis and treatment using medications.

    Check out the top 18 biotech companies you should add to your portfolio:

    BioLineRx Ltd. (NASDAQ: BLRX)

    BioLineRx Ltd. (NASDAQ: BLRX) shares were trading up 33.78% at $1.98 at the time of writing on Friday. BioLineRx Ltd. (NASDAQ: BLRX) share price went from a low point around $1.06 to briefly over $3.04 in the past 52 weeks, though shares have since pulled back to $1.98. BLRX market cap has remained high, hitting $39.57M at the time of writing. BioLineRx Ltd. (BLRX) has earlier announced the promising results from the ongoing GENESIS Phase III trial motixafortide for stem cell mobilization (SCM) in multiple myeloma patients.

    Miragen Therapeutics Inc. (NASDAQ: MGEN)

    Miragen Therapeutics Inc. (NASDAQ: MGEN) last closed at $1.31, in a 52-week range of $0.31 to $2.27. Miragen Therapeutics Inc. (MGEN) has earlier acquired  Viridian Therapeutics, Inc. It has traded up 321.22% and traded down -42.29% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 4.80 and a quick ratio of 4.80. This company has a market capitalization of $79.29 million at the time of writing.

    Equillium Inc. (NASDAQ: EQ)

    Equillium Inc. (NASDAQ: EQ) stock soar by 5.83% to $6.35. The most recent rating by H.C. Wainwright, on July 14, 2020, is at a Buy. Previously, Equillium Inc. (EQ) has revealed that it has received a ‘Study May Proceed letter’ from the U.S. Food and Drug Administration (FDA) to commence a Phase 3 clinical trial, titled  EQUINOX, evaluating itolizumab in hospitalized COVID-19 patients suffering from acute respiratory distress syndrome (ARDS).

    Titan Pharmaceuticals Inc. (NASDAQ: TTNP)

    Titan Pharmaceuticals Inc. (NASDAQ: TTNP) shares headed falling, lower as much as -3.24%. The most recent rating by Maxim Group, on June 26, 2019, is at a Buy. Titan Pharmaceuticals Inc. (TTNP) revealed the pricing of an underwritten public offering of 80,000,000 units at a price of $0.10 per unit. Each unit issued in the offering comprised of one share of common stock and one warrant to purchase one share of common stock.

    Trevena Inc. (NASDAQ: TRVN)

    Trevena Inc. (NASDAQ: TRVN) rose 2.34% after gaining more than $0.06 on Friday. Trevena Inc. (TRVN) has disclosed that oliceridine has been classified as a Schedule II controlled substance by the U.S. Drug Enforcement Administration (DEA). Looking at its liquidity, it has a current ratio of 16.20 and a quick ratio of 16.20. This company has a market capitalization of $381.29 million at the time of writing.

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) last closed at $6.94, in a 52-week range of $1.45 to $19.39. Sorrento Therapeutics Inc. (SRNE) has earlier announced preclinical data about intravenous COVI-AMG™ (STI-2020; Affinity Matured COVI-GUARD) neutralizing antibody (nAb) in a preprint publication.

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) shares headed falling, lower as much as -1.69%. The most recent rating by Alliance Global Partners, on June 26, 2020, is at a Buy. iBio Inc. (IBIO) has earlier appointed Dr. Alexandra Kropotova to its Board of Directors, effective as of October 14, 2020. Dr. Kropotova has also been chosen as a member of iBio’s new Science & Technology Committee, which shall be chaired by Dr. Philip Russell.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) fall -6.10% after losing more than -$0.64 on Friday. Inovio Pharmaceuticals Inc. (INO) announced that it is scheduled to release its third-quarter financial results of 2020 on November 9, 2020.  This company has a market capitalization of $1.76 billion at the time of writing.

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (NASDAQ: VXRT) last closed at $4.92, in a 52-week range of $0.27 to $17.49. A class action has started on behalf of certain shareholders in Vaxart, Inc. It has traded up 1749.62% and traded down -71.87% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 4.00 and a quick ratio of 4.00. This company has a market capitalization of $580.22 million at the time of writing.

    Axovant Gene Therapies Ltd. (NASDAQ: AXGT)

    Axovant Gene Therapies Ltd. (NASDAQ: AXGT) stock drop by -41.64% to $2.13. The most recent rating by Cantor Fitzgerald, on April 17, 2020, is at an Overweight. Axovant Gene Therapies Ltd. (AXGT) has earlier announced program updates on Friday, October 30, 2020, at 11:30 AM Eastern time, for the Company’s AXO-Lenti-PD gene therapy for Parkinson’s disease.

    Akebia Therapeutics Inc. (NASDAQ: AKBA)

    Akebia Therapeutics Inc. (NASDAQ: AKBA) shares headed falling, lower as much as -2.20%. The most recent rating by Needham, on November 14, 2019, is at a Buy. Akebia Therapeutics Inc. (AKBA) earlier revealed that it is scheduled to announce its financial results for the third quarter ended September 30, 2020, on November 5, 2020, before the opening of the market.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) fall -5.35% after losing more than -$3.81 on Friday. Moderna Inc. (MRNA) earlier revealed that it has been recognized as one of the global biopharmaceutical industry’s top employers in Science and ScienceCareers’ 2020 Top Employers Survey for the sixth consecutive year.

    Heat Biologics Inc. (NASDAQ: HTBX)

    Heat Biologics Inc. (NASDAQ: HTBX) stock soar by 3.45% to $1.20. The most recent rating by B. Riley Securities, on October 14, 2020, is at a Buy. Heat Biologics Inc. (HTBX) share price went from a low point around $0.19 to briefly over $4.30 in the past 52 weeks, though shares have since pulled back to $1.20. HTBX market cap has remained high, hitting $172.30 Million at the time of writing.

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) last closed at $0.26, in a 52-week range of $0.10 to $1.56. Onconova Therapeutics Inc. (ONTX) revealed that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update during the 2020 BIO Investor Forum Digital event taking place October 13-15.

    Clovis Oncology Inc. (NASDAQ: CLVS)

    Clovis Oncology Inc. (NASDAQ: CLVS) stock drop by -4.27% to $4.93. The most recent rating by H.C. Wainwright, on May 18, 2020, is at a Buy. Clovis Oncology Inc. (CLVS) is scheduled to release its third-quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m.

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX)

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares headed rising, higher as much as 2.41%. The most recent rating by JP Morgan, on September 29, 2020, is at an Overweight. BioCryst Pharmaceuticals Inc. (BCRX) revealed that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted oral, once-daily berotralstat a positive scientific opinion through the Early Access to Medicines Scheme (EAMS).

    Soligenix Inc. (NASDAQ: SNGX)

    Soligenix Inc. (NASDAQ: SNGX) rose 0.59% after gaining more than $0.01 on Friday. Soligenix Inc. (SNGX) has disclosed that continued optional treatment with SGX301 across all lesions during the compassionate use, safety portion of the trial (Cycle 3), for a total of 6 months in the study, continued to significantly improve responses and remained safe and well-tolerated in its FLASH study.

    Scholar Rock Holding Corporation (SRRK)

    Scholar Rock Holding Corporation (SRRK) last closed at $38.90, in a 52-week range of $6.95 to $46.50. Analysts have a consensus price target of $30.00. Scholar Rock Holding Corporation (SRRK) announced the pricing of an underwritten public offering of 2,948,718 shares of its common stock at a public offering price of $39.00 per share.